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Upfront Surgery versus 
Neoadjuvant Therapy for 
Resectable Pancreatic Cancer: 
Systematic Review and Bayesian 
Network Meta-analysis
Alison Bradley ?ǡ ? & Robert Van Der Meer ?
Current treatment recommendations for resectable pancreatic cancer support upfront resection and 
Ǥơ
approach are lacking. This review aims to compare both treatment strategies for resectable pancreatic 
Ǥǡǡǡ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
cancer. A Bayesian network meta-analysis was conducted using the Markov chain Monte Carlo method. 
ǯǡǦ
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Pancreatic cancer (PC) is the fourth and ith most common cause of cancer deaths in the USA and Europe 
respectively1,2. Despite advances in surgical technique and adjuvant treatment, survival rates remain poor1,2. 
Early complete surgical resection is the only potentially curative treatment for PC and adjuvant therapy has been 
proven to prolong survival leading to surgery irst with adjuvant therapy (SFadj) becoming the standard of care 
for resectable pancreatic cancer (RPC)3. However in reality most patients develop early recurrence, nullifying 
the potential beneits of high-risk surgery4 with up to 50% of patients failing to receive adjuvant therapy due to: 
post-operative complications, early metastases, reduced performance status and comorbidities5. his has resulted 
in the advent of neoadjuvant therapy (NAT) with the postulated beneits of: identifying aggressive tumour hence 
avoiding futile surgery, elimination of micrometastesis, increased feasibility of R0 resection and completion of 
multimodal treatment6,7.
NAT for RPC is an area of prime controversy and ongoing debate with a lack of large prospective randomised 
controlled trials (RCTs) ofering direct comparison with SFadj approach8. Ambiguity surrounding the existing 
body of research has led critics to highlight the limitations of drawing optimistic conclusions from small stud-
ies that are underpowered and caution against loosing the window of resectability6,7. Although not their sole 
focus, meta-analysis by both Xu et al.9 and Andriulli et al.10 report only marginal beneit of NAT in terms of 
overall and disease-free survival in RPC7, whilst other studies report superiority of NAT approach for RPC11–14. 
Previous Markov decision analysis studies have reported slight beneit with NAT11,13,15. Oten comparison studies 
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include borderline resectable and locally advanced PC in NAT arm hence they do not ofer a true like-for-like 
comparison.
In the clinical setting the role of NAT has widely been accepted for the management of locally advanced and 
borderline resectable cases of PC to increase the likelihood of achieving resection, particularly R0 resection6–8,13. 
However, ambiguities in the existing body of research concerning the management of RPC with either SFadj or 
NAT approach creates a dilemma in clinical decision-making. It has been established that optimal survival out-
comes for PC are not obtained by resection alone, but require the delivery of additional treatment whether deliv-
ered as neoadjuvant or adjuvant therapy3,9–15. Both SFadj and NAT treatment approaches carry the risk of failing 
to achieve multimodal treatment delivery. he currently recommended standard of care for RPC, SFadj3, carries 
the risk of failing to receive adjuvant therapy despite having undergone surgery with its associated risks of mor-
bidity and mortality4,5. NAT approach also carries the risk of disease that was initially resectable at presentation 
progressing to become unresectable which makes its role in the management of RPC controversial6,7. he ques-
tion therefore arises as to whether NAT represents a less superior treatment approach to SFadj for RPC, or if NAT 
has the advantage of identifying aggressive tumour types, that would have resulted in early disease reoccurrence 
precluding adjuvant therapy, being identiied prior to patients undergoing high-risk, costly yet futile surgery6,7. 
he aim of this review is to compare SFadj and NAT approach to the management of RPC on an intention-to-treat 
basis. Treatment outcomes include: R0 resection rates and 1, 2, 3, 4 and 5-year survival.
Methods
he protocol for this review was published in the PROSPERO online database of systematic reviews (CRD42018108673). 
his review followed the PRISMA checklist16.
A search was undertaken using MEDLINE, Embase, PubMed and Cochrane database. For each of the four 
searches, the entire database was included since 2000 up to and including 31st August 2018, with no further date 
restrictions or limits applied. Full search strategies and are detailed in supplementary material (Supplementary 
Methods1).
Search Strategy. Ater removal of duplicates, manual screening was carried out based on the title and 
abstract of articles identiied in the database searches. Articles of probable or possible relevance to this review 
based on the title and abstract were reviewed in full. Following screening, reference lists and citations of all 
included papers were manually searched to identify any additional articles. his process was repeated until no 
new articles were identiied.
Inclusion Criteria and Outcomes. RCTs and Prospective phase II and III trials ofering comparison of NAT 
and SFadj approach for RPC, published in English language since 2000, involving chemo/radiotherapy-naive 
human subjects over 18 years of age with preoperatively staged RPC, or that reported outcomes for RPC sepa-
rately, were included. As this produced only 2 studies prospective and retrospective cohort studies comparing 
NAT and SFadj, with the same inclusion criteria, were also included. RCTs comparing SFadj and surgery alone, 
with similar inclusion criteria, were also included for sensitivity analysis. Included trials had to report: protocol 
design, treatment regimes, number per arm, median age and co-morbidities of subjects, pre-treatment stage of 
pancreatic cancer, outcome from post NAT re-staging, surgical outcomes including resection rates, R0 resection 
rates and survival time. Case series and case reports were excluded, as were studies from identical patient cohorts. 
Studies that included borderline resectable, locally advanced and stage IV pancreatic cancer where results were 
inseparable, trials involving intra-operative radiotherapy and trials including disease other than pancreatic cancer 
were excluded.
Data collection. Search design and data extraction were performed by the lead reviewer and with sec-
ond author performing independent quality assurance. Discrepancies were resolved by discussion between the 
reviewers. he following data was extracted from each study: study details (country, year, design, number of 
participants, mean age, sex, co-morbidity proile and presenting disease stage of participants in each arm), details 
of treatment protocols, treatment outcomes (rates of tumour resection, R0 resection rates, overall survival and 
disease free survival and 1, 2, 3, 4 and 5 year survival rates) and risk of bias data.
he Cochrane Collaboration’s risk of bias tool17 and ROBINS-I tool (Risk Of Bias In Non-randomized Studies 
- of Interventions)18. Grading of Recommendations Assessment Development and Evaluation (GRADE) tool 
was used to provide additional assessment of quality of evidence and rate certainty in estimates from network 
meta-analysis19,20.
Statistical analysis. his study was conducted on an intention-to-treat basis. Patients who dropped out, 
or who failed to receive multimodal treatment within, either SFadj or NAT pathways in the included studies 
were included in the overall and disease free survival analysis. he number of patients in the NAT pathway who 
presented with RPC but failed to undergo resection, and the number of patients who underwent surgery but 
failed to receive adjuvant therapy, were analysed using weighted pooled estimates of proportions calculated using 
Freeman-Tukey arcsine square root transformation under random efects model to account for heterogeneity.
For each outcome of interest, NetMetXl was used to draw a weighted network for all treatments assessed for 
the speciic outcomes that accounted for the study population size of each included study21–23. his ensured that 
larger studies carried a greater weight within the network. A Bayesian network meta-analysis was conducted 
using the Markov chain Monte Carlo method in WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, and 
Imperial College School of Medicine, London, UK). To account for the inherent heterogeneity as a result of the 
diferent chemotherapy regimes, variations in multimodal treatment completion rates and diferences in reported 
survival outcomes, analysis was run using a random efects, in addition to a ixed efects, model using vague 
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priors as outlined in National Institute of Clinical Excellence Evidence Synthesis Series21,24,25. Pairwise compari-
sons between interventions were also summarized to provide ranking of impact of intervention on outcome based 
on the surface under the cumulative ranking (SUCRA) and summarized in rankograms21,25.
To further minimise the impact of heterogeneity of different chemotherapy combinations, treatment 
completion rates and reported survival analysis on the overall analysis, convergence was assessed using the 
Brooks-Gelman-Rubin method and by checking whether the Monte Carlo error is less than 5% of the stand-
ard deviation of the efect estimates and between-study variance21. he Markov chain Monte Carlo (MCMC) 
Bayesian network meta-analysis was itted with three chains as a means of checking MCMC convergence21. he 
Brooks-Gelman-Rubin method compares within-chain and between-chain variances to calculate the potential 
scale reduction factor with a value close to one indicating when approximate convergence is reached21,26.
Inconsistency assessment, the conflict between direct and indirect evidence, is crucial to any network 
meta-analysis27. In accordance with the NICE decision-support documents28 inconsistency was measured by 
comparing deviance residuals and deviance information criteria (DIC) statistic in itted consistency and inconsist-
ency models21,27. Posterior mean deviance of the individual data points in the inconsistency model were plotted 
against their posterior mean deviance in the consistency model to identify any loops in the treatment network 
where inconsistency is present21.
A sensitivity network meta-analysis was carried out that also included RCTs that compared SFadj and surgery 
only.
Results
Eligible studies. A total of 14224 studies were identiied through search of electronic databases (Medline/
PubMed: 148; Embase: 14032; Cochrane Database: 1; Cochrane Trial Registry: 43). Ater removal of dupli-
cates and studies that were not relevant on review of title and abstract, 452 studies underwent full text review 
(Supplementary Fig. 1a). 9 studies were identiied that ofered comparison between NAT and SFadj for treatment 
of RPC29–37. As only 2 of these studies were phase II trials29,30, one of which was randomized29 all studies were 
therefore included in the network meta-analysis. 4 studies were prospective31–34 and 3 studies were retrospec-
tive35–37 (Supplementary Table 1a; Supplementary Fig. 2).
6 studies (n = 371) reported the number of cases of RPC who received NAT and progressed to sur-
gery29–31,33,34,37 giving a pooled proportion of 76.08% (95% CI: 60.826–88.509). Two studies reported response 
to NAT29,31. One study reported responses for resectable cases29 (complete response: 0; partial response: 4/31; 
stable disease 8/31; disease progress 12/31; 7 unrecorded). he study by Ielop et al.31 did not report this outcome 
separately for resectable only cases but included borderline cases also in reporting the outcomes of response to 
NAT (complete response: 5/45; partial response: 13/45; stable disease 5/45). 6 studies (n = 17596) reported the 
number of patients in the SFadj pathway who received adjuvant therapy31–33,35–37 giving a pooled proportion of 
63.01% (95% CI: 59.452–66.489).
For sensitivity analysis, RCTs ofering comparison between surgery and adjuvant therapy versus surgery 
alone were also included in a separate network meta-analysis. Electronic database search identiied 25332 stud-
ies (Medline/PubMed: 3165; Embase: 21810; Cochrane Database: 1; Cochrane Trial Registry: 356). 15 studies 
were randomized controlled trials, 5 of which ofered comparison between adjuvant therapy and surgery alone 
and were included in the sensitivity analysis (Supplementary Fig. 1b; Supplementary Table 1b; Supplementary 
Fig. 2b)38–42.
A summary of overall indings for each outcome measure is provided in Fig. 1.
 ?Ǥ he network ofering pairwise comparison of rates of R0 resection between NAT and 
SFadj included 8 studies and 9197 participant (NAT: n = 2626; SFadj: n = 6571). he aggregate rate of R0 resection 
for NAT was 0.8008 (0.3636–0.9144) compared to 0.7515 (0.2826–0.8611) for SFadj. Both ixed efects (O.R: 1.49; 
Figure 1. Summary of results of Bayesian network meta-analysis comparing upfront surgery and adjuvant 
therapy with neoadjuvant therapy for the management of resectable pancreatic cancer.
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95% CI: 1.32–1.68) and random efects (O.R: 1.27; 95% CI: 0.60–1.96) models favoured NAT. NAT was found to 
have superior positive impact on outcome of R0 resection (SUCRA: 0.8124 versus 0.1876).
 ?ǦǤ Pairwise comparison for 1-year survival of NAT versus SFadj was based on 8 studies 
and 12011 participants (NAT: n = 2708; SFadj: n = 9303). Aggregate rate of 1-year survival was higher in NAT 
at 0.7969 (0.6061–0.9500) versus 0.7481 (0.4848–0.8500). Both ixed efects (O.R. 1.46 95% CI: 1.31–1.63) and 
random efects (O.R. 1.38 95% CI: 0.69–2.96) models favoured NAT. NAT also has a stronger positive impact on 
the outcome of 1-year survival (SUCRA: 0.84 v 0.16).
For sensitivity analysis a network also including RCTs of SFadj versus surgery only was constructed based on 
a total of 10 studies and 12483 patients (NAT: n = 2708; SFadj: n = 9540; Surgery only: n = 235). 8 studies com-
pared NAT and SFadj (n = 12011) and 2 studies compared SFadj and surgery only (n = 472). NAT was found to 
be superior in both ixed and random efects models (Supplementary Fig. 3). Aggregate rate of 1-year survival 
was highest in NAT (0.7957; range 0.6205–0.9500) followed by SFadj (0.7478; range 0.4848–0.8500) then surgery 
only (0.7314; range 0.7250–0.7500). Again NAT was found to have strongest positive impact on outcome of 1-year 
survival (SUCRA 0.7836; Supplementary Fig. 3c).
 ?ǦǤ Network pairwise comparison of NAT and SFadj for 2-year survival was based on 7 
studies (n = 4251; NAT n = 903; SFadj: 3348). Aggregate rate of 2-year survival was 0.5178 (0.3000–0.5970) versus 
0.5131 (0.2727–0.5346) in favour of NAT. Both ixed efects (O.R. 1.22; 95% CI: 1.02–1.46) and random efects 
model (O.R. 1.26; 95% CI: 0.94–1.74) favoured NAT with SUCRA 0.95 for NAT.
Inclusion of SFadj versus Surgery only RCTs in a network based on 9 studies (n = 4723; NAT: n = 903; SFadj: 
n = 3585; Surgery only: n = 235) also demonstrated superiority of NAT for 2-year survival in both ixed and 
random efects model (Supplementary Fig. 4). Aggregate of 2-year survival was 0.5217 (0.3000–0.5970) for NAT 
compared to 0.5107 (0.2727–0.5346) for SFadj and 0.4149 (0.4000–0.4200) for surgery only.
 ?ǦǤ Pairwise comparison of NAT versus SFadj was based on a network comprising 8 
studies (n = 12011; NAT: n = 2708; SFadj: n = 9303) and demonstrated superiority of NAT with aggregate rate of 
0.3367 (0.1212–0.3900) to 0.2943 (0.1800–0.4700). Again both ixed efect (O.R. 1.25 95% CI 1.14–1.38) and ran-
dom efects (O.R. 1.19 9% CI 0.86–1.51) models favored NAT with SUCRA 0.9 demonstrating stronger positive 
efect with NAT on outcomes of 3-year survival.
Inclusion of SFadj versus Surgery only RCTs in a network produced comparisons based on 9 studies (n = 12365; 
NAT: 2708; SFadj: n = 9482; Surgery only: n = 175). NAT was superior in both ixed and random efects models 
with aggregate rate 0.3400 (0.2000–0.4194) compared to 0.2951 (0.1800–0.4700) for SFadj and 0.2050 (0.2050–
0.2050) for surgery only (Supplementary Fig. 5).
 ?ǦǤ Only pairwise comparison of NAT and SFadj could be ofered, as SFadj versus sur-
gery only RCTS did not report 4-year survival rates. his network was based on 4 studies (n = 656). NAT was 
superior with aggregate rate 0.1416 (0.0303–0.2500) compared to 0.1269 (0.0606–0.2000). Fixed efects (O.R. 1.16 
95% 0.69–1.94) and random efects model (O.R 1.03 95% CI 0.27–3.13) favored NAT.
 ?ǦǤ Network pairwise comparison of 5-year survival for NAT and SFadj was based on 
7 studies (n = 8896; NAT: n = 2558; SFadj: n = 6338). Aggregate rate for NAT was 0.2069 (0.0323–0.3300) com-
pared to 0.1783 (0.0606–0.2300). Fixed efects (O.R 2.21 95% CI: 1.07–1.37) and random efects (vague prior) 
(O.R. 1.19 95% 0.65–1.73) favored NAT with SUCRA 0.82 for NAT association with 5-year survival.
Inclusion of SFadj versus surgery only RCTs was based on 11 studies (n = 9675; NAT n = 2558; SFadj n = 6730; 
Surgery only n = 387). NAT was superior across ixed efects and random efects models with aggregate rate 
0.2069 (0.0323–0.3300) followed by 0.1814 (0.0606–0.2640) for SFadj and 0.1418 (0.1040–0.2200) for surgery 
only (Supplementary Fig. 6).
ǡǤ Convergence 
was achieved across all models and no issues were identiied with inconsistency. In 2-year survival analysis and 
5-year survival analysis there was a marginal preference towards ixed efects model as determined by the DIC 
statistic.
Overall this analysis marginally favors NAT for treatment of RPC across outcomes of R0 resection, 1, 2, 3, 4 
and 5-year survival. his is based on the best available studies and did not alter on sensitivity analysis. However, 
issues pertaining to quality and level of bias of available studies are an issue that weakens the strength and level of 
certainty of any such recommendations (Supplementary Fig. 7).
Discussion
SFadj is a well established treatment pathway for RPC3. NAT is supported by current guidelines for borderline 
resectable and locally advanced PC but its role in the management of RPC remains controversial8,13. Postulated 
beneits of NAT include: identifying aggressive tumour types hence avoiding futile surgery, elimination of micro-
metastesis, increased R0 resection rate and increased rate of completion of multimodal treatment considering 
that up to 50% of patients treated in SFadj pathway fail to receive adjuvant therapy5–7. However, controversy in 
the role of NAT for RPC arises from the potential of loosing the window of resectability6,7. In the absence of con-
clusive results from large multi-centered RCTs, this study, the irst of its kind, utilizes existing studies comparing 
NAT and SFadj for the treatment of RPC in a Bayesian network meta-analysis to ofer an important interim 
source of information to inform the ongoing debate regarding the best treatment for RPC.
In terms of survival time, from direct and indirect comparisons our analysis found that NAT was marginally 
superior to SFadj across 1, 2, 3, 4 and 5-year survival. hese indings are corroborated by previous attempts to 
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synthesize existing evidence comparing SFadj and NAT for RPC. Meta-analysis by both Xu et al.9 and Andriulli et al.10 
reported marginal beneit of NAT for RPC in terms of OS and DFS for resectable cases. However, neither of these 
reports focused solely on NAT and therefore omitted signiicant studies from their meta-analysis7. Sharma et al.11 
and de Gus et al.13 synthesized published data in a Markov decision-analysis model to compared NAT and SFadj 
for the treatment of RPC and also reported marginal beneit of NAT. More recently Versteijne et al.14 reported 
more signiicant survival beneit with NAT in their meta-analysis but the reported weighted mean overall survival 
time included borderline resectable cases therefore captured the efect of conversion to resectability afecting 
overall survival time in NAT pathway. he reported weighted mean overall survival time for resectable only cases 
was lower although still superior to SFadj14.
he second key outcome explored through direct and indirect comparison was the rate of R0 resection, which 
is known to impact survival time43. Once again NAT was found to be superior to SFadj which is in keeping with 
the hypothesis that NAT results in higher rates of R0 resection6,7,44. However, deinitions of R0 resection can vary 
between studies, which could potentially impact reported outcomes14. In this study convergence was achieved 
across all models comparing this outcome and no issues with inconsistency were identiied in our analysis.
A key clinical concern when selecting a treatment pathway for RPC is the delivery of multimodal treatment: 
resection in the NAT pathway and receipt of adjuvant therapy in the SFadj pathway. Our analysis of pooled 
proportions found that 63% of patients in the SFadj pathway received adjuvant therapy, and 76% in the NAT 
pathway underwent resection. hese indings are in keeping with the results of a recent meta-analysis of pooled 
proportions that reported 68.6% of patients in SFadj received adjuvant therapy and 76.8% of resectable cases in 
NAT pathways underwent resection14.
A strength of this study is that only studies of RPC, identiied through comprehensive literature search, were 
included to ofer a true like-for-like comparison based on currently available evidence. Analysis of NAT versus 
SFadj were based on direct comparisons to strengthen certainty of indings with indirect comparisons drawn 
from inclusion of SFadj versus surgery only in sensitivity analysis which did not alter network indings. However, 
this study also shares the limitations of the existing body of evidence pertaining to treatment of RPC: hetero-
geneity and small underpowered sample size10. Although random efects modeling was employed to counter 
heterogeneity, overall there is a lack of RCTs comparing NAT and SFadj for RPC7,10,11,13. Only one of the two 
phase II trials were randomized29 with the remaining studies being either prospective or retrospective studies 
which raises serous concerns about bias and reduced certainty in the recommendations drawn from the network 
meta-analysis. However, unlike the majority of existing network meta-analysis45–47, this study went beyond only 
assessing bias of included trials to utilise GRADE approach to rate the certainty in estimates from our network 
meta-analysis20,48–51. Hence this study not only furthers the ongoing current debate regarding best treatment for 
RPC by ofering an important interim analysis, but adds a further dimension by highlighting limitations of the 
body of evidence on which this analysis is based.
To conclude our Bayesian network meta-analysis shows that NAT for treatment of RPC is no worse than tra-
ditional SFadj approach and may even hold beneit across outcomes of: R0 resection, 1, 2, 3, 4 and 5-year survival. 
his inding in the context of limitations of existing studies means that conclusive superiority of one approach 
over another for RPC cannot be determined without a degree of uncertainty. his highlights three important 
directions for future research: 1) rigorous head-to-head comparison of NAT and SFadj for treatment of RPC 2) 
cost-efectiveness analysis of NAT versus SFadj and 3) exploring methods of predictive statistical modeling to 
identify patients who are more likely to receive and beneit from difering treatment modalities within competing 
pathways. By moving research in this direction it is hoped that we can ind a path from ambiguity to delivering 
personalized medicine with associated beneits for patients and resource utilization.
Data Availability
he datasets analysed during the current study are publicly available and sources are cited in supplementary 
material.
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